Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Surgery
1.2.3 Drugs
1.2.4 Vitamin D
1.2.5 Calcimimetics
1.2.6 Phosphate Binders
1.3 Market by Application
1.3.1 Global Secondary Hyperparathyroidism Treatment Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2018-2033)
2.2 Secondary Hyperparathyroidism Treatment Growth Trends by Region
2.2.1 Global Secondary Hyperparathyroidism Treatment Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Size by Region (2018-2023)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Region (2024-2033)
2.3 Secondary Hyperparathyroidism Treatment Market Dynamics
2.3.1 Secondary Hyperparathyroidism Treatment Industry Trends
2.3.2 Secondary Hyperparathyroidism Treatment Market Drivers
2.3.3 Secondary Hyperparathyroidism Treatment Market Challenges
2.3.4 Secondary Hyperparathyroidism Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2018-2023)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
3.4 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.4.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2022
3.5 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.6 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.7 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Secondary Hyperparathyroidism Treatment Breakdown Data by Type
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2018-2023)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2024-2033)
5 Secondary Hyperparathyroidism Treatment Breakdown Data by Application
5.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Application (2018-2023)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2018-2033)
6.2 North America Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2018-2033)
7.2 Europe Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size (2018-2033)
8.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Secondary Hyperparathyroidism Treatment Market Size (2018-2033)
9.2 Latin America Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023)
9.4 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size (2018-2033)
10.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
11.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 OPKO Health
11.2.1 OPKO Health Company Detail
11.2.2 OPKO Health Business Overview
11.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
11.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.2.5 OPKO Health Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
11.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Detail
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
11.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.4.5 Astellas Pharma Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
11.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.5.5 Roche Recent Development
11.6 KAI Pharmaceuticals
11.6.1 KAI Pharmaceuticals Company Detail
11.6.2 KAI Pharmaceuticals Business Overview
11.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.6.5 KAI Pharmaceuticals Recent Development
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Detail
11.7.2 Kyowa Hakko Kirin Business Overview
11.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
11.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.7.5 Kyowa Hakko Kirin Recent Development
11.8 Leo Pharma
11.8.1 Leo Pharma Company Detail
11.8.2 Leo Pharma Business Overview
11.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
11.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.8.5 Leo Pharma Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
11.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.9.5 Takeda Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
11.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 Deltanoid Pharmaceuticals
11.11.1 Deltanoid Pharmaceuticals Company Detail
11.11.2 Deltanoid Pharmaceuticals Business Overview
11.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023)
11.11.5 Deltanoid Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Surgery
Table 3. Key Players of Drugs
Table 4. Key Players of Vitamin D
Table 5. Key Players of Calcimimetics
Table 6. Key Players of Phosphate Binders
Table 7. Global Secondary Hyperparathyroidism Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Secondary Hyperparathyroidism Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Secondary Hyperparathyroidism Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Secondary Hyperparathyroidism Treatment Market Share by Region (2018-2023)
Table 11. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Secondary Hyperparathyroidism Treatment Market Share by Region (2024-2033)
Table 13. Secondary Hyperparathyroidism Treatment Market Trends
Table 14. Secondary Hyperparathyroidism Treatment Market Drivers
Table 15. Secondary Hyperparathyroidism Treatment Market Challenges
Table 16. Secondary Hyperparathyroidism Treatment Market Restraints
Table 17. Global Secondary Hyperparathyroidism Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Secondary Hyperparathyroidism Treatment Market Share by Players (2018-2023)
Table 19. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2022)
Table 20. Ranking of Global Top Secondary Hyperparathyroidism Treatment Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Secondary Hyperparathyroidism Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
Table 24. Date of Enter into Secondary Hyperparathyroidism Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Secondary Hyperparathyroidism Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2018-2023)
Table 28. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2024-2033)
Table 30. Global Secondary Hyperparathyroidism Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Application (2018-2023)
Table 32. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Application (2024-2033)
Table 34. North America Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 49. Amgen Company Detail
Table 50. Amgen Business Overview
Table 51. Amgen Secondary Hyperparathyroidism Treatment Product
Table 52. Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 53. Amgen Recent Development
Table 54. OPKO Health Company Detail
Table 55. OPKO Health Business Overview
Table 56. OPKO Health Secondary Hyperparathyroidism Treatment Product
Table 57. OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 58. OPKO Health Recent Development
Table 59. AbbVie Company Detail
Table 60. AbbVie Business Overview
Table 61. AbbVie Secondary Hyperparathyroidism Treatment Product
Table 62. AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 63. AbbVie Recent Development
Table 64. Astellas Pharma Company Detail
Table 65. Astellas Pharma Business Overview
Table 66. Astellas Pharma Secondary Hyperparathyroidism Treatment Product
Table 67. Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 68. Astellas Pharma Recent Development
Table 69. Roche Company Detail
Table 70. Roche Business Overview
Table 71. Roche Secondary Hyperparathyroidism Treatment Product
Table 72. Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 73. Roche Recent Development
Table 74. KAI Pharmaceuticals Company Detail
Table 75. KAI Pharmaceuticals Business Overview
Table 76. KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Product
Table 77. KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 78. KAI Pharmaceuticals Recent Development
Table 79. Kyowa Hakko Kirin Company Detail
Table 80. Kyowa Hakko Kirin Business Overview
Table 81. Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Product
Table 82. Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 83. Kyowa Hakko Kirin Recent Development
Table 84. Leo Pharma Company Detail
Table 85. Leo Pharma Business Overview
Table 86. Leo Pharma Secondary Hyperparathyroidism Treatment Product
Table 87. Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 88. Leo Pharma Recent Development
Table 89. Takeda Company Detail
Table 90. Takeda Business Overview
Table 91. Takeda Secondary Hyperparathyroidism Treatment Product
Table 92. Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 93. Takeda Recent Development
Table 94. Sanofi Company Detail
Table 95. Sanofi Business Overview
Table 96. Sanofi Secondary Hyperparathyroidism Treatment Product
Table 97. Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 98. Sanofi Recent Development
Table 99. Deltanoid Pharmaceuticals Company Detail
Table 100. Deltanoid Pharmaceuticals Business Overview
Table 101. Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Product
Table 102. Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2018-2023) & (US$ Million)
Table 103. Deltanoid Pharmaceuticals Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Secondary Hyperparathyroidism Treatment Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Secondary Hyperparathyroidism Treatment Market Share by Type: 2022 VS 2033
Figure 3. Surgery Features
Figure 4. Drugs Features
Figure 5. Vitamin D Features
Figure 6. Calcimimetics Features
Figure 7. Phosphate Binders Features
Figure 8. Global Secondary Hyperparathyroidism Treatment Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2022 VS 2033
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Secondary Hyperparathyroidism Treatment Report Years Considered
Figure 13. Global Secondary Hyperparathyroidism Treatment Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Secondary Hyperparathyroidism Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Secondary Hyperparathyroidism Treatment Market Share by Region: 2022 VS 2033
Figure 16. Global Secondary Hyperparathyroidism Treatment Market Share by Players in 2022
Figure 17. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Secondary Hyperparathyroidism Treatment Revenue in 2022
Figure 19. North America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Secondary Hyperparathyroidism Treatment Market Share by Country (2018-2033)
Figure 21. United States Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Secondary Hyperparathyroidism Treatment Market Share by Country (2018-2033)
Figure 25. Germany Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Secondary Hyperparathyroidism Treatment Market Share by Region (2018-2033)
Figure 33. China Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Secondary Hyperparathyroidism Treatment Market Share by Country (2018-2033)
Figure 41. Mexico Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Secondary Hyperparathyroidism Treatment Market Share by Country (2018-2033)
Figure 45. Turkey Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Amgen Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 48. OPKO Health Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 49. AbbVie Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 50. Astellas Pharma Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 51. Roche Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 52. KAI Pharmaceuticals Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 53. Kyowa Hakko Kirin Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 54. Leo Pharma Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 55. Takeda Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 56. Sanofi Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 57. Deltanoid Pharmaceuticals Revenue Growth Rate in Secondary Hyperparathyroidism Treatment Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed